GV20 oncotherapy Co., Ltd.

GV20 ONCOTHERAPY

GV20 Oncotherapy was started by expert team from Harvard University. We are devoted in cancer immuno-oncology precision medicine development. GV20 Oncotherapy has created new generation of cancer novel drug discovery and development platform which integrates cancer genomics, antibody drug design and biological big data mining. We are utilizing our technological advantages to search novel immuno-oncology targets, screen tumor-specific fully human antibody and identify robust response biomarkers.

Technology platforms

Novel Immuno-Oncology Targets

Tumor-Specific Fully Human Antibodies

Robust Response Biomarkers

Atlas Genomics PlatformTumor profile,CRISPR screen &
antibody screen

Phial AI PlatformBig data & machine learning algorithms

company culture

Vision

Promote and realize precision medical services
Value

Looking for truth, embracing technological innovation, learning and progressing
Mission

Using functional genomics and bio-big data technology to advance cancer precision medicine innovation

investors

Linear Capital
IDG
WATSON

Vision

Value

Mission

Linear Capital

IDG

WATSON